Skip to main content
SpringerLink
Log in

Portal vein thrombosis in patients with cirrhosis: underdiagnosis and undertreatment?

  • IM - COMMENTARY
  • Published:
Internal and Emergency Medicine Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Violi F, Corazza RG, Caldwell SH, Perticone F, Gatta A, Angelico M, Farcomeni A, Masotti M, Napoleone L, Vestri A, Raparelli V, Basili S, Collaborators P-L (2016) Portal vein thrombosis relevance on liver cirrhosis: italian Venous Thrombotic Events Registry. Intern Emerg Med. doi:10.1007/s11739-016-1416-8

    Google Scholar 

  2. Fimognari FL, Violi F (2008) Portal vein thrombosis in liver cirrhosis. Intern Emerg Med 3(3):213–218. doi:10.1007/s11739-008-0128-0

    Article  PubMed  Google Scholar 

  3. DeLeve LD, Valla DC, Garcia-Tsao G, American Association for the Study Liver Diseases (2009) Vascular disorders of the liver. Hepatology 49(5):1729–1764. doi:10.1002/hep.22772

    Article  CAS  PubMed  Google Scholar 

  4. Senzolo M, Riggio O, Primignani M, Italian Association for the Study of the Liver ad hoc (2011) Vascular disorders of the liver: recommendations from the Italian Association for the Study of the Liver (AISF) ad hoc committee. Dig Liver Dis 43(7):503–514. doi:10.1016/j.dld.2010.11.006

    Article  PubMed  Google Scholar 

  5. Stine JG, Shah PM, Cornella SL, Rudnick SR, Ghabril MS, Stukenborg GJ, Northup PG (2015) Portal vein thrombosis, mortality and hepatic decompensation in patients with cirrhosis: a meta-analysis. World J Hepatol 7(27):2774–2780. doi:10.4254/wjh.v7.i27.2774

    Article  PubMed  PubMed Central  Google Scholar 

  6. Qi X, De Stefano V, Li H, Dai J, Guo X, Fan D (2015) Anticoagulation for the treatment of portal vein thrombosis in liver cirrhosis: a systematic review and meta-analysis of observational studies. Eur J Intern Med 26(1):23–29. doi:10.1016/j.ejim.2014.12.002

    Article  CAS  PubMed  Google Scholar 

  7. Delgado MG, Seijo S, Yepes I, Achecar L, Catalina MV, Garcia-Criado A, Abraldes JG, de la Pena J, Banares R, Albillos A, Bosch J, Garcia-Pagan JC (2012) Efficacy and safety of anticoagulation on patients with cirrhosis and portal vein thrombosis. Clin Gastroenterol Hepatol 10(7):776–783. doi:10.1016/j.cgh.2012.01.012

    Article  PubMed  Google Scholar 

  8. Chung JW, Kim GH, Lee JH, Ok KS, Jang ES, Jeong SH, Kim JW (2014) Safety, efficacy, and response predictors of anticoagulation for the treatment of nonmalignant portal-vein thrombosis in patients with cirrhosis: a propensity score matching analysis. Clin Mol Hepatol 20(4):384–391. doi:10.3350/cmh.2014.20.4.384

    Article  PubMed  PubMed Central  Google Scholar 

  9. Kearon C, Akl EA, Comerota AJ, Prandoni P, Bounameaux H, Goldhaber SZ, Nelson ME, Wells PS, Gould MK, Dentali F, Crowther M, Kahn SR, American College of Chest Physicians (2012) Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141(2 Suppl):e419S–e494S. doi:10.1378/chest.11-2301

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. de Franchis R, Baveno VIF (2015) Expanding consensus in portal hypertension: Report of the Baveno VI Consensus Workshop: stratifying risk and individualizing care for portal hypertension. J Hepatol 63(3):743–752. doi:10.1016/j.jhep.2015.05.022

    Article  PubMed  Google Scholar 

  11. De Stefano V, Martinelli I (2010) Splanchnic vein thrombosis: clinical presentation, risk factors and treatment. Intern Emerg Med 5(6):487–494. doi:10.1007/s11739-010-0413-6

    Article  PubMed  Google Scholar 

  12. Haas CE, Nelsen JL, Raghavendran K, Mihalko W, Beres J, Ma Q, Forrest A (2005) Pharmacokinetics and pharmacodynamics of enoxaparin in multiple trauma patients. J Trauma 59(6):1336–1343 (discussion 1343–1334)

    Article  CAS  PubMed  Google Scholar 

  13. Arjal R, Trotter JF (2009) International normalized ratio of prothrombin time in the model for end-stage liver disease score: an unreliable measure. Clin Liver Dis 13(1):67–71. doi:10.1016/j.cld.2008.09.009

    Article  PubMed  Google Scholar 

  14. Finazzi G, Ageno W (2016) Direct oral anticoagulants in rare venous thrombosis. Intern Emerg Med 11(2):167–170. doi:10.1007/s11739-016-1398-6

    Article  PubMed  Google Scholar 

  15. Potze W, Arshad F, Adelmeijer J, Blokzijl H, van den Berg AP, Porte RJ, Lisman T (2013) Routine coagulation assays underestimate levels of antithrombin-dependent drugs but not of direct anticoagulant drugs in plasma from patients with cirrhosis. Br J Haematol 163(5):666–673. doi:10.1111/bjh.12593

    Article  CAS  PubMed  Google Scholar 

  16. Hu TY, Vaidya VR, Asirvatham SJ (2016) Reversing anticoagulant effects of novel oral anticoagulants: role of ciraparantag, andexanet alfa, and idarucizumab. Vasc Health Risk Manag 12:35–44. doi:10.2147/VHRM.S89130

    PubMed  PubMed Central  Google Scholar 

  17. Aslan AN, Sari C, Bastug S, Sari SO, Akcay M, Durmaz T, Bozkurt E (2016) Severe jaundice due to intrahepatic cholestasis after initiating anticoagulation with rivaroxaban. Blood Coagul Fibrinolysis 27(2):226–227. doi:10.1097/MBC.0000000000000442

    Article  CAS  PubMed  Google Scholar 

  18. Anastasia EJ, Rosenstein RS, Bergsman JA, Parra D (2015) Use of apixaban after development of suspected rivaroxaban-induced hepatic steatosis; a case report. Blood Coagul Fibrinolysis 26(6):699–702. doi:10.1097/MBC.0000000000000363

    Article  PubMed  Google Scholar 

  19. Liakoni E, Ratz Bravo AE, Terracciano L, Heim M, Krahenbuhl S (2014) Symptomatic hepatocellular liver injury with hyperbilirubinemia in two patients treated with rivaroxaban. JAMA Intern Med 174(10):1683–1686. doi:10.1001/jamainternmed.2014.3912

    Article  PubMed  Google Scholar 

  20. Russmann S, Niedrig DF, Budmiger M, Schmidt C, Stieger B, Hurlimann S, Kullak-Ublick GA (2014) Rivaroxaban postmarketing risk of liver injury. J Hepatol 61(2):293–300. doi:10.1016/j.jhep.2014.03.026

    Article  CAS  PubMed  Google Scholar 

  21. Watkins PB, Desai M, Berkowitz SD, Peters G, Horsmans Y, Larrey D, Maddrey W (2011) Evaluation of drug-induced serious hepatotoxicity (eDISH): application of this data organization approach to phase III clinical trials of rivaroxaban after total hip or knee replacement surgery. Drug Saf 34(3):243–252. doi:10.2165/11586600-000000000-00000

    Article  PubMed  Google Scholar 

  22. Bondarenko M, Curti C, Montana M, Rathelot P, Vanelle P (2013) Efficacy and toxicity of factor Xa inhibitors. J Pharm Pharm Sci 16(1):74–88

    Article  CAS  PubMed  Google Scholar 

  23. Baig M, Wool KJ, Halanych JH, Sarmad RA (2015) Acute liver failure after initiation of rivaroxaban: a case report and review of the literature. N Am J Med Sci 7(9):407–410. doi:10.4103/1947-2714.166221

    Article  PubMed  PubMed Central  Google Scholar 

  24. Caldeira D, Barra M, Ferreira A, Rocha A, Augusto A, Pinto FJ, Costa J, Ferreira JJ (2015) Systematic review with meta-analysis: the risk of major gastrointestinal bleeding with non-vitamin K antagonist oral anticoagulants. Aliment Pharmacol Ther 42(11–12):1239–1249. doi:10.1111/apt.13412

    Article  CAS  PubMed  Google Scholar 

  25. Loffredo L, Perri L, Violi F (2015) Impact of new oral anticoagulants on gastrointestinal bleeding in atrial fibrillation: a meta-analysis of interventional trials. Dig Liver Dis 47(5):429–431. doi:10.1016/j.dld.2015.01.159

    Article  CAS  PubMed  Google Scholar 

  26. Chan EW, Lau WC, Leung WK, Mok MT, He Y, Tong TS, Wong IC (2015) Prevention of dabigatran-related gastrointestinal bleeding with gastroprotective agents: a population-based study. Gastroenterology 149(3):586–595 e583. doi:10.1053/j.gastro.2015.05.002

    Article  CAS  PubMed  Google Scholar 

  27. Caldeira D, Barra M, Santos AT, de Abreu D, Pinto FJ, Ferreira JJ, Costa J (2014) Risk of drug-induced liver injury with the new oral anticoagulants: systematic review and meta-analysis. Heart 100(7):550–556. doi:10.1136/heartjnl-2013-305288

    Article  CAS  PubMed  Google Scholar 

  28. Lenz K, Dieplinger B, Buder R, Piringer P, Rauch M, Voglmayr M (2014) Successful treatment of partial portal vein thrombosis (PVT) with low dose rivaroxaban. Z Gastroenterol 52(10):1175–1177. doi:10.1055/s-0034-1385171

    Article  CAS  PubMed  Google Scholar 

  29. Pannach S, Babatz J, Beyer-Westendorf J (2013) Successful treatment of acute portal vein thrombosis with rivaroxaban. Thromb Haemost 110(4):626–627. doi:10.1160/TH13-05-0407

    Article  CAS  PubMed  Google Scholar 

  30. Intagliata NM, Maitland H, Northup PG, Caldwell SH (2015) Treating thrombosis in cirrhosis patients with new oral agents: ready or not? Hepatology 61(2):738–739. doi:10.1002/hep.27225

    Article  CAS  PubMed  Google Scholar 

  31. Martinez M, Tandra A, Vuppalanchi R (2014) Treatment of acute portal vein thrombosis by nontraditional anticoagulation. Hepatology 60(1):425–426. doi:10.1002/hep.26998

    Article  CAS  PubMed  Google Scholar 

  32. Intagliata NM, Henry ZH, Maitland H, Shah NL, Argo CK, Northup PG, Caldwell SH (2016) Direct oral anticoagulants in cirrhosis patients pose similar risks of bleeding when compared to traditional anticoagulation. Dig Dis Sci. doi:10.1007/s10620-015-4012-2

    PubMed  Google Scholar 

  33. Graff J, Harder S (2013) Anticoagulant therapy with the oral direct factor Xa inhibitors rivaroxaban, apixaban and edoxaban and the thrombin inhibitor dabigatran etexilate in patients with hepatic impairment. Clin Pharmacokinet 52(4):243–254. doi:10.1007/s40262-013-0034-0

    Article  CAS  PubMed  Google Scholar 

  34. Potze W, Adelmeijer J, Lisman T (2015) Decreased in vitro anticoagulant potency of rivaroxaban and apixaban in plasma from patients with cirrhosis. Hepatology 61(4):1435–1436. doi:10.1002/hep.27350

    Article  CAS  PubMed  Google Scholar 

  35. Kubitza D, Roth A, Becka M, Alatrach A, Halabi A, Hinrichsen H, Mueck W (2013) Effect of hepatic impairment on the pharmacokinetics and pharmacodynamics of a single dose of rivaroxaban, an oral, direct Factor Xa inhibitor. Br J Clin Pharmacol 76(1):89–98. doi:10.1111/bcp.12054

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Potze W, Arshad F, Adelmeijer J, Blokzijl H, van den Berg AP, Meijers JC, Porte RJ, Lisman T (2014) Differential in vitro inhibition of thrombin generation by anticoagulant drugs in plasma from patients with cirrhosis. PLoS One 9(2):e88390. doi:10.1371/journal.pone.0088390

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Ageno W, Riva N, Schulman S, Beyer-Westendorf J, Bang SM, Senzolo M, Grandone E, Pasca S, Di Minno MN, Duce R, Malato A, Santoro R, Poli D, Verhamme P, Martinelli I, Kamphuisen P, Oh D, D’Amico E, Becattini C, De Stefano V, Vidili G, Vaccarino A, Nardo B, Di Nisio M, Dentali F (2015) Long-term clinical outcomes of splanchnic vein thrombosis: results of an International Registry. JAMA Intern Med 175(9):1474–1480. doi:10.1001/jamainternmed.2015.3184

    Article  PubMed  Google Scholar 

  38. Riva N, Ageno W, Poli D, Testa S, Rupoli S, Santoro R, Lerede T, Piana A, Carpenedo M, Nicolini A, Ferrini PM, Tosetto A, Italian Federation of Anticoagulation Clinics (FCSA) (2015) Safety of vitamin K antagonist treatment for splanchnic vein thrombosis: a multicenter cohort study. J Thromb Haemost 13(6):1019–1027. doi:10.1111/jth.12930

    Article  CAS  PubMed  Google Scholar 

  39. Ageno W, Riva N, Schulman S, Bang SM, Sartori MT, Grandone E, Beyer-Westendorf J, Barillari G, Di Minno MN, Dentali F, IRSVT Study Group (2014) Antithrombotic treatment of splanchnic vein thrombosis: results of an international registry. Semin Thromb Hemost 40(1):99–105. doi:10.1055/s-0033-1363473

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Portiuncula University Hospital & Galway University Hospital, Saolta University Health Care Group, Galway, Ireland

    Aaron Liew

  2. National University of Ireland Galway (NUIG), Galway, Ireland

    Aaron Liew

  3. Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, NE2 4HH, UK

    Aaron Liew

  4. St. Joseph’s Healthcare, Department of Medicine, McMaster University, F-544, 50 Charlton Ave East, Hamilton, ON, L8N 4A6, Canada

    James Douketis

Authors
  1. Aaron Liew
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. James Douketis
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to James Douketis.

Ethics declarations

Conflict of interest

Dr. Aaron Liew perceives no conflict of interest with this manuscript but has participated in Advisory Boards for Novo Nordisk, Sanofi, and Janssen. He has previously received educational and research support from AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Pfizer, Daichii Sankyo, Merck Sharp & Dohme, Novo Nordisk, Novartis, Sanofi-Aventis and Medtronic. Dr. James Douketis perceives no conflict of interest with this manuscript but has participated in Advisory Boards or Educational Activities for Bayer, Bristol-Myers-Squibb, Sanofi, Astra-Zeneca, Boehringer-Ingelheim, Pfizer, Biotie, Portola, The Medicines and Daiichi-Sankyo. He also participated as a consultant to Actelion, AGEN Biomedical, Ortho-Janssen Pharmaceuticals, Boehringer-Ingelheim and Janssen Pharmaceuticals. He has previously received grant support from Boehringer-Ingelheim.

Statement of human and animal rights

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all individual participants included in the study.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Liew, A., Douketis, J. Portal vein thrombosis in patients with cirrhosis: underdiagnosis and undertreatment?. Intern Emerg Med 11, 1037–1040 (2016). https://doi.org/10.1007/s11739-016-1463-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11739-016-1463-1

Keywords

Search

Navigation